Research on the prevention and treatment of synbiotheics for autoimmune diseases via the mucosal immune.

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K11597
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59040:Nutrition science and health science-related
• Research Institution: Nara Medical University
• Principal Investigator: Kubo Kaoru 奈良県立医科大学, 医学部, 研究員 (20254493)
• Co-Investigator(Kenkyū-buntansha): 友田 恒一 川崎医科大学, 医学部, 教授 (90364059)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: シンバイオテイクス / 関節リウマチ / 腸内細菌叢

Outline of Final Research Achievements

For the purpose of improving the effect of symbiothetics on rheumatoid arthritis, we examined the reproducibility of the reduction effect of adjuvant arthritis by ingestion of GFOB, a special feed containing 5% bifidobacterium longum to cellulose deficiency AIN-93G containing 2% glutamine, 3.2% polydextrose, and 3% lactulose. Individuals with loose stools or diarrhea appeared after induction of adjuvant arthritis, and reproducibility was not obtained. Next, a collagen arthritis model was examined, and although no individual disorder appeared, no alleviating effect was observed. GFOB intake tended to lower serum endotoxin levels, but did not affect the expression of ZO-1 and did not increase the amount of IgA in the cecum.

Free Research Field

実験動物学

Academic Significance and Societal Importance of the Research Achievements

シンバイオテイクス【GFOB, G:グルタミン, F:食物繊維（ポリデキストロース）, O:オリゴ糖（ラクチュロース）, B:ビフィズス菌 の混合物（混合比率: 2%: 3.2%: 3%: 5%）】の8週間給餌によりLewis系ラットのアジュバント関節炎の腫脹と骨破壊が有意に軽減されることを見出した。加えて、腸内細菌叢のBacterodetes門とFirmicutes門の不均衡が改善され、酢酸と酪酸の糞便中濃度が有意に増加した。シンバイオテイクスは、扱いやすくヒトへの安全性が高く、さらなる研究開発により、食品製造分野や医薬製造分野での製品化への可能性は高いと考えられる。